RoukenBio’s Year in Review

2024 has been a big year for RoukenBio and the wider biotech space!  

Beginning with our multimillion-pound investment from NorthEdge at the end of last year, we’ve seen our rebrand to RoukenBio – CRO redefined. This better reflects our Scottish roots and our disruptive place in the CRO space.

Our Rouken Discovery Centre is transforming with the 560m² expansion of modern lab and office spaces – physically reinforcing our new company look. 

2024 also saw the launch of our brand-new Bruker biosensor, the heliXcyto. While our trademark IndEx-2 dual inducible system continues to innovate drug discovery.

Overall, RoukenBio reflects Scotland's flourishing life science landscape – level with the biotech loci in England and the US.

An award-winning year

Our hard work this year hasn’t gone unnoticed; our CSO Dr Agapitos Patakas was the proud recipient of SelectScience’s prestigious Webinar of the Year Award! The winning webinar covers our in vitro T cell exhaustion model in collaboration with Agilent Technologies. 

“We are honoured to win!” said Agi. “Our model addresses the unmet need for a biologically relevant, human in vitro model for T cell exhaustion. This is just one example of our extensive immunology capabilities and demonstrates how we apply these to accelerate the drug development programmes of our customers.” 

RoukenBio was shortlisted for Scotland’s Life Sciences Business Leadership Award 2024! Notably, we were the only finalist in this category who entered as a team. We also struck up partnerships with various organisations including Black Professionals United Kingdom, SULSA, and ScreenIn3D.

RoukenBio’s going global 

We travelled far and wide this year, attending 15 industry conferences! 

Our 15 RoukenBio delegates visited 10 cities across the world, from Boston to Basel. We chatted to over 300 experts, giving away around 400 of our cuddly highland cows! Did you spot us? 

Next year, we’ll be pushing to attend major American conferences. We’ll be starting off next year’s season at the IO360 Summit Boston in March. We hope to meet you there! Where would you like to see us next? 

Looking forward

Despite continued challenges in the biotech space, we’re anticipating a prosperous new year. The official opening of our Phase II building development is due in January. Science-wise, we’re working to expand into therapeutic areas like allergy and inflammation. 

All of our efforts at RoukenBio fall under a shared aim: to use our brilliant minds to deliver quality drug discovery data. 

We can’t wait to see what we’ll discover in 2025.